Vimarsana
Biggest News Aggregation in the World

Page 18 - Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Solid Tumors Today - Breaking & Trending Today

KPIX CBS Evening News With Jeff Glor April 2, 2019 - Vimarsana News

KPIX CBS Evening News With Jeff Glor April 2, 2019

Glor and, some hospitals turned them away. Six months later, an inspiring update on baby ivy. There really arent any words to describe how thankful we are that we have her. Glor good evening. Im jeff glor. And this is our western edition. Well begin tonight with a whistleblower at the white house. A longtime employee of the White House Personnel Security Office claims 25 people denied clearances because of disqualifying issues in their backgrounds were granted access anyway. The head of a Congressional Committee sent a letter asking why some aides were given security clearances. The group in q...

U.S. Food and Drug Administration Approves Augtyrotm (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors - Vimarsana News

U.S. Food and Drug Administration Approves Augtyrotm (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that...

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer - Vimarsana News

Dostarlimab With Carboplatin/Paclitaxel Shows Survival Benefits in dMMR/MSI-H Endometrial Cancer

Dostarlimab plus carboplatin and paclitaxel improved PFS and OS in dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting - Vimarsana News

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 -- Merus N.V. , a clinical-stage oncology company developing innovative, full-length multispecific antibodies , today announced updated...

Merus N.V.: Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC - Vimarsana News

Merus N.V.: Merus' Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024(Nasdaq: MRUS) (Merus, the Company